open access

Vol 7, No 4 (2011)
Review paper
Published online: 2011-10-26
Get Citation

Inhibition of molecular signaling of epidermal growth factor receptor (EGFR) and its clinical potential for treating renal cell cancer

Gabriel Wcisło, Cezary Szczylik
Onkol. Prak. Klin 2011;7(4):197-207.

open access

Vol 7, No 4 (2011)
REVIEW ARTICLES
Published online: 2011-10-26

Abstract

Renal cell cancer affects circa 3% of cancer patients diagnosed with malignant disease. We have seen achievements in the treatment of renal cell cancer patients in advanced or metastatic stage for more than ten years. New therapies appeared to be a result of many experimental investigations that let us know pathophysiology of renal cell cancer at the molecular levels. Among well-defined molecular targets, EGFR (epidermal growth factor receptor) seems to have a role when its blocking could provide clinical benefits to renal cell cancer patients. Molecular signaling of EGFR is a crucial factor during development and progression in many malignant diseases. Renal cell cancer is not unveiled at the molecular levels of EGFR functions, and the same limited knowledge is the indirect result of clinical trials some EGFR inhibiting agents, already useful in medical practice of patients with colorectal cancer, head and neck malignancies or breast cancer. This paper presents a role of EGFR signaling in a renal cell cancer cell, and moreover, early results in some of more advanced clinical trials have been described as well.
Onkol. Prak. Klin. 2011; 7, 4: 197–207

Abstract

Renal cell cancer affects circa 3% of cancer patients diagnosed with malignant disease. We have seen achievements in the treatment of renal cell cancer patients in advanced or metastatic stage for more than ten years. New therapies appeared to be a result of many experimental investigations that let us know pathophysiology of renal cell cancer at the molecular levels. Among well-defined molecular targets, EGFR (epidermal growth factor receptor) seems to have a role when its blocking could provide clinical benefits to renal cell cancer patients. Molecular signaling of EGFR is a crucial factor during development and progression in many malignant diseases. Renal cell cancer is not unveiled at the molecular levels of EGFR functions, and the same limited knowledge is the indirect result of clinical trials some EGFR inhibiting agents, already useful in medical practice of patients with colorectal cancer, head and neck malignancies or breast cancer. This paper presents a role of EGFR signaling in a renal cell cancer cell, and moreover, early results in some of more advanced clinical trials have been described as well.
Onkol. Prak. Klin. 2011; 7, 4: 197–207
Get Citation

Keywords

renal cell cancer; EGFR; targeted therapy

About this article
Title

Inhibition of molecular signaling of epidermal growth factor receptor (EGFR) and its clinical potential for treating renal cell cancer

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 4 (2011)

Article type

Review paper

Pages

197-207

Published online

2011-10-26

Bibliographic record

Onkol. Prak. Klin 2011;7(4):197-207.

Keywords

renal cell cancer
EGFR
targeted therapy

Authors

Gabriel Wcisło
Cezary Szczylik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl